The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

The resignation of the FDA's head drug regulator George Tidmarsh comes amid concerns about conduct related to lupus nephritis drug Lupkynis.

Their combined market capitalisation rose 4% from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025.

The ‘Risk to Reasons’ initiative aims to engage women and HCPs across the UK in non- judgemental conversations about HIV prevention.

US consumer health company Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for ...

The FDA has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic mitochondrial disease, thymidine kinase 2 ...

Eli Lilly and Company has outlined plans to develop a $3bn manufacturing facility in Katwijk, Leiden Bio Science Park, the ...

Prostate cancer rates are up 10% in the UK since 2016 - a rise which is attributed to an ageing population and improved ...

Alvotech, with its strategic commercialisation partner Advanz Pharma, received EMA approval for Mynzepli (AVT06) in August ...

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market ...